Merck & Co.MRK

01Keytruda's indication breadth across 45+ approved uses creates multiple demand vectors that compound as earlier-stage indications gain utilization, while the 2.5% royalty expiration at year-end 2026 will structurally improve margins on the franchise going forward.

02Multiple recently launched products—Winrevair in PAH, Welireg in RCC, Capvaxive in pneumococcal disease, Ohtuvayre in COPD—are scaling rapidly enough to diversify revenue away from Keytruda concentration and offset declining franchises like Januvia/Janumet.

03Merck is deploying substantial capital to acquire differentiated clinical-stage assets—an oral CML therapy and a long-acting influenza prophylactic—that address large patient populations with distinct mechanisms, while external funding partnerships defray development risk.

04The $3 billion annual cost-savings target by end-2027 provides a self-funded source of reinvestment into launches and R&D, partially insulating margins even if IRA price-setting and biosimilar erosion pressure top-line growth.